1. Home
  2. FGI vs GNPX Comparison

FGI vs GNPX Comparison

Compare FGI & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FGI Industries Ltd.

FGI

FGI Industries Ltd.

N/A

Current Price

$3.93

Market Cap

7.5M

Sector

Industrials

ML Signal

N/A

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$2.01

Market Cap

6.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FGI
GNPX
Founded
1987
2009
Country
United States
United States
Employees
420
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5M
6.4M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
FGI
GNPX
Price
$3.93
$2.01
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
8.0K
830.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
76.33
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$3.80
N/A
Revenue Next Year
$6.26
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.46
$0.14
52 Week High
$12.62
$12.97

Technical Indicators

Market Signals
Indicator
FGI
GNPX
Relative Strength Index (RSI) 37.05 47.20
Support Level $3.88 $1.90
Resistance Level $4.65 $2.51
Average True Range (ATR) 0.47 0.17
MACD -0.08 0.01
Stochastic Oscillator 32.89 23.85

Price Performance

Historical Comparison
FGI
GNPX

About FGI FGI Industries Ltd.

FGI Industries Ltd is a supplier of kitchen and bath products. The company is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. The company offers products that fall into four categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The company generates the majority of its revenue from the sale of Sanitaryware products. Geographically, the company generates the majority of its revenue from the United States, followed by Canada and Europe.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Share on Social Networks: